Could anifrolumab be the next hope for HS patients?
NCT ID NCT06374212
First seen Jan 25, 2026 · Last updated May 13, 2026 · Updated 25 times
Summary
This study tests whether anifrolumab, a drug that blocks certain immune processes, can help people with hidradenitis suppurativa (HS) — a painful skin condition causing boils and tunnels. About 15 adults with moderate-to-severe HS will receive the drug intravenously over 24 weeks. Researchers will measure if symptoms improve by at least 50% and track quality of life changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UNC Dermatology and Skin Cancer Center
Chapel Hill, North Carolina, 27516, United States
Conditions
Explore the condition pages connected to this study.